INTRODUCTION

Pseudoephedrine is a direct and indirect acting sympathomimetic agent. It is a steroisomer of ephedrine and has similar actions. Pseudoephedrine and its salts are given orally for the symptomatic relief of nasal congestion. They are also commonly combined with other ingredients in preparations intended for the relief of cough and cold symptoms. Some cases of adverse cutaneous effects associated with pseudoephedrine have been reported (recurrent pseudo-scarlatina, fixed drug eruptions, erythematous macular rash, systemic contact dermatitis...). Considering the frequent use of pseudoephedrine, associated drug eruptions generally appear to be rare.

Phenylephrine is a sympathomimetic agent with mainly direct effects on \( \alpha \)-adrenergic receptors. It has been used parenterally in the treatment of hypotensive states, but this drug and its salts are more commonly employed as local vasoconstrictors, either topically or by mouth for the symptomatic relief of nasal congestion, and in ophthalmology as a mydriatic or as a conjunctival decongestant (1). Since the first description of allergic contact dermatitis from phenylephrine in eye drops in 1979, further cases have been described; however, it seems to be a rare condition despite extensive use by ophthalmologists (2-21).

SUMMARY

Background: Phenylephrine and pseudoephedrine are sympathomimetic drugs belonging to the phenylamine family. Adverse cutaneous effects associated with these drugs have been reported but, in view of their frequent use, appear to be rare. The very close chemical structures of these drugs could explain potential cross-reactions among them but the results reported in the literature are controversial.

Case report: An 18-year-old woman developed blepharoconjunctivitis after application of phenylephrine and tropicamide eye drops. Four years after this reaction, she took 1 tablet of Narine\textsuperscript{®} (pseudoephedrine and loratadine) and 3-4 hours later developed a generalized erythrodermic reaction. Cutaneous biopsy revealed hydropic changes in the basal layer and, in the dermis, moderate edema with slight perivascular lymphocyte and eosinophil infiltrates. Patch tests with European standard series, commercial eye drops, tropicamide, phenylephrine, pseudoephedrine and other sympathomimetic agents were applied to the patient’s back. After 47 and 96 hours, only the patches with pseudoephedrine and phenylephrine were positive.

Conclusions: We believe that our patient has presented two different reactions with different clinical outcome and histopathology, which are unlikely to be due to cross-reactivity between the drugs involved. We have found no similar coincidences reported in the literature.

Key words: Allergic contact dermatitis. Cross-reactivity. Cutaneous adverse drug reactions.
We report the case of a patient who had an allergic contact dermatitis due to phenylephrine in eye drops and some years later an erythrodermia after oral ingestion of pseudoephedrine. We have not found any case similar to this in the literature.

Case report

A 18-year-old woman was referred to our outpatient clinic because she had developed 6 months before pruritus with slight erythema in the trunk that became generalized until erythrodermia was finally produced. This reaction happened 3-4 hours after taking a tablet of Narine® (pseudoephedrine and loratadine). The patient was treated with systemic corticosteroids and antihistamines. She presented generalized skin desquamation and the complete resolution of the symptoms was in 2 weeks.

Four years before, she had suffered eyelid erythema, ocular itching and conjunctival hyperemia 24 hours after the application of 2 kinds of eye drops: Oculos Fenilefrina® 10 % (phenylephrine) and Colircusi Tropicamida® (tropicamide). The reaction resolved with topical corticosteroids within 5-7 days.

The patient had previously tolerated these drugs. After that, she had employed some eye drops with local anesthetics, cyclopentolate and atropine, and oral loratadine without problems.

Patch tests with European standard series, Oculos Fenilefrina® 10 % and Colircusi Tropicamida® eye drops, pseudoephedrine, phenylephrine and other sympathomimetic agents were applied to the patient’s back. The patch tests were removed after 48 hours, and readings were performed at 48 and 96 hours according to the recommendations of the ECDRG (European Contact Dermatitis Research Group). The European standard series and Colircusi Tropicamida® eye drop proved negative. After 48 hours the patches with Oculos Fenilefrina® 10 % eye drop, pseudoephedrine and phenylephrine were positive (table I).

Excipients in Oculos Fenilefrina® 10 % eye drop were not tested because we confirmed that they were included in other eye drops that the patient used without problems.

We informed our patient that she had to avoid both drugs, phenylephrine and pseudoephedrine, but 4 months later she consulted again with an erythrodermic reaction after having taken “one tablet” for cold symptoms. We confirmed that this tablet included pseudoephedrine. A cutaneous biopsy was carried out showing hydropic changes in the basal layer and, in the dermis, moderate edema with slight perivascular infiltrate of lymphocytes and eosinophils.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Concentration (%)</th>
<th>Vehicle</th>
<th>Results (48/96 h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ephedrine</td>
<td>1</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td>Pseudoephedrine</td>
<td>1</td>
<td>Petrolatum</td>
<td>+ / +</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Petrolatum</td>
<td>++ / ++</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Petrolatum</td>
<td>+++ / +++</td>
</tr>
<tr>
<td>Norephedrine</td>
<td>1</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td>Phenylephrine</td>
<td>1</td>
<td>Petrolatum</td>
<td>+ / +</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Petrolatum</td>
<td>++ / ++</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Petrolatum</td>
<td>+++ / +++</td>
</tr>
<tr>
<td>Epinephrine</td>
<td>1</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>Petrolatum</td>
<td>Negative</td>
</tr>
</tbody>
</table>

The reaction resolved with oral antihistamines and corticosteroids within 7 days.

Discussion

We present a patient with 2 delayed cutaneous reactions from 2 sympathomimetic drugs: an allergic contact dermatitis due to phenylephrine and an erythrodermia due to pseudoephedrine. Although there are several reports of allergic contact dermatitis caused by phenylephrine (2-21), we have only found 2 cases of erythrodermia related with pseudoephedrine (22, 23) and no cases of both reactions in the same patient as in our case.

Both drugs belong to the phenylamine family, which comprises 2 main groups of drugs: phenylpropanolamin-derived (ephedrine, pseudoephedrine, and norephedrine) and phenylethanolamin-derived (phenylephrine and epinephrine) (1). The very close chemical structures of these drugs could explain potential crossreactions among them. Although some authors have observed cross-reactions between ephedrine and pseudoephedrine (24, 25), others have not (26). Interestingly, in some cases patch tests proved positive with pseudoephedrine and phenylephrine with not clinical relevance (25, 26). Audicana et al reported a case of generalized eczema caused by...
pseudoeindhovenine taken orally in a patient with previous allergic contact dermatitis by phenylephrine (14). In our case, the histology is similar to that described in the case of Vega et al (27) and ruled out the diagnosis of eczema. So, we think that our patient has presented 2 different reactions with different clinical evolution and histopathology, probably not due to cross-reactivity between the drugs incriminated. We have not found similar coincidence in the literature.

RESUMEN

Antecedentes: La fenilefrina y la pseudoeodefdrina son fármacos simpaticomiméticos que pertenecen a la familia fenilamina. Teniendo en cuenta el amplio uso de estos fármacos, las reacciones adversas cutáneas producidas por ellos no parecen frecuentes. La similitud química de estas sustancias podría explicar la existencia de reacciones cruzadas entre ellas, pero los resultados de la literatura sobre este tema son controvertidos.

Caso clínico: Mujer de 18 años de edad, remitida a nuestras consultas por haber presentado a las 3-4 horas de tomar un comprimido de Narine® (lortadina y pseudoeodefdrina) una reacción eritrodermica generalizada. Cuatro años antes había presentado una blefaroconjuntivitis tras la aplicación sintomática de 2 colirios, Oculos Fenilefrina® 10 % y Colircusi Tropicamida®. Las pruebas epicutáneas con la batería estándar del GEIDC, los colirios comerciales y con 2 colirios, Oculos Fenilefrina® y pseudoefedrina sólo dieron positivas con fenylephrine y pseudoefedrina a las 3-4 horas de haber tomado el medicamento. Eritrodermia. Colirio. Pruebas de parche. Fenilefrina. Pseudoefedrina.

Conclusiones: Se trata de 2 reacciones diferentes tanto clínica como histopatológicamente, probablemente no explicables por la posible reactividad cruzada entre los fármacos implicados. No hemos encontrado coincidencias similares en la literatura.


REFERENCES


